Hormone-blocking therapy used by the male population to treat prostate cancer may increase their risk of developing colon cancer, according to a study published in the Journal of the National Cancer Institute.

The drug treatment is called ‘androgen deprivation therapy’ also known as ADT, which is used to suppress the production of male hormone testosterone which increases the development of prostate cancer.

ADT is commonly used to treat prostate cancer even though it has known potential effects such as diabetes and obesity. Diabetes and obesity are the two main risk factors in the development of colon cancer.

The U.S Food and Drug Administration just informed last month that hormonal treatments for prostate cancer such as Lupron and Trelstar should bear new warnings regarding their potential risks of heart problems and diabetes.

According to the researchers, studies in animals suggested that the male hormones stop the signals that cause cancer cells to grow, which in turn suppresses the development of colon cancer.

The authors say it might be possible that inhibiting the release of hormones in the body could lead to greater risk for colon cancer.

Dr. Vahakn Shahinian of the University of Michigan, along with his colleagues studied more than 100,000 older men that were diagnosed with prostate cancer between the years 1993 and 2002.

They discovered that those men who received ADT had about 30 to 40 percent greater risk of developing colon cancer during the follow-up period. However, the case is still based on an observational study, and not a proven cause and effect.